All In Biotech

Drug Trial Radar · NCT06158490

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

An Efficacy and Safety Study of JYP0061 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial

Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

120

Planned (sponsor's estimate)

Start

Dec 27, 2023

Primary completion

Feb 10, 2026

Study completion Oct 10, 2026

Sponsor

Lead sponsor
Guangzhou JOYO Pharma Co., LtdIndustry
Sponsor type
Industry
First posted
Dec 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are: * The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis. * The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis. Participants will: * Be treated with either a low-dose or high-dose of JYP0061. * Undergo efficacy and safety evaluations as stipulated in the trial protocol.

Conditions

  • Moderate-to-severe Atopic Dermatitis

Interventions

  • JYP0061 15 mgDrug

    Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.

  • JYP0061 30 mgDrug

    articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.

  • PlaceboDrug

    Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75) from baseline.Time frame: Evaluations will be conducted weekly for up to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.